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ABSTRACT 
Aim To evaluate the cost-effectiveness of needle and syringe programmes (NSPs) compared 
to no NSPs on hepatitis C virus (HCV) transmission in the United Kingdom. 
Design Cost-effectiveness analysis from NHS/ health-provider perspective, utilising a dynamic 
transmission model of HCV infection and disease progression, calibrated using city-specific 
surveillance and survey data, and primary data collection on NSP costs. The effectiveness of 
NSPs preventing HCV acquisition was based on empirical evidence. 
Setting UK settings with different chronic HCV prevalence among people who inject drugs 
(PWID): Dundee (26%), Walsall (18%), and Bristol (45%) 
Population PWID 
Interventions Current NSP provision is compared to a counterfactual scenario where NSPs 
are removed for 10 years and then returned to existing levels with effects collected for 40 
years.  
Measurements HCV infections, and cost per quality adjusted life year (QALY) gained through 
NSPs over 50 years   
Findings Compared to a willingness-to-pay threshold of £20,000 per QALY gained, NSPs were 
highly cost-effective over a time-horizon of 50 years and decreased the number of HCV 
incident infections. The mean incremental cost-effectiveness ratio was cost-saving in Dundee 
and Bristol, and £596 per QALY gained in Walsall, with 78%, 46% and 40% of simulations being 
cost-saving in each city, respectively, with differences driven by coverage of NSP and HCV 
prevalence (lowest in Walsall). Over 90% of simulations were cost-effective at the willingness-
to-pay threshold.  Results were robust to sensitivity analyses including varying the time-
horizon, HCV treatment cost and numbers of HCV treatments per year.   
Conclusions We projected NSPs avert HCV infections and are highly cost-effective in the UK 
and could be cost-saving to the NHS and other health care providers. NSPs will remain cost-
effective in the UK irrespective of changes in HCV treatment cost and scale-up, meaning that 
NSPs will continue to be an efficient strategy for preventing HCV transmission in the future. 
Abbreviations: 
HCV, Hepatitis C Virus; PWID, People who inject drugs; NSP, Needle and syringe programmes; 
IPED, image and performance enhancing drugs; OST, opioid substitution therapy; HCNSP, high 
coverage needle and syringe provision; QALY, quality adjusted life year;  ICER, incremental 
cost effectiveness ratio; WTP, willingness to pay; NMB, Net monetary benefit; HIV Human 
Immunodeficiency Virus  
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MAIN TEXT 
INTRODUCTION 
Hepatitis C virus (HCV) is a global public health issue, with an estimated 71 million people 
living with HCV[1, 2]. In the UK, approximately 200,000 are chronically infected, with 90% of 
new infections occurring among people who inject drugs (PWID)[3, 4]. Similar epidemics exist 
in other high-income settings[5]. To reduce the burden of HCV, it is crucial to reduce the 
incidence of HCV among PWID[6].  
In most settings, needle and syringe programmes (NSPs) are the primary intervention for 
reducing the transmission of blood borne viruses among PWID. NSPs provide sterile needles, 
syringes, injecting equipment, and other prevention and support services. There is good 
evidence that NSPs reduce injecting risk behaviours, and can prevent the acquisition of HCV 
and HIV amongst PWID[7-13].   
Previous research has shown that NSPs are a cost-effective intervention to reduce HIV 
incidence in multiple settings[14-21]. However, only two studies have considered their cost-
effectiveness in reducing HCV incidence[22, 23], with no studies from western Europe. In the 
UK, funding for NSPs is under threat due to budget cuts and shifting emphasis of drug policy 
to recovery and abstinence-based treatment programmes[24]. To improve the evidence base 
and inform policy choices, it is therefore important to assess the cost-effectiveness of NSP. 
We evaluated the cost-effectiveness of current levels of NSP provision on the transmission 
and disease burden of HCV in three UK settings, compared to a counterfactual of no NSP 
provision. 
METHODS  
Setting and Intervention 
The intervention considered was needle and syringe distribution services to prevent HCV 
transmission. NSPs in the UK can be provided through several modalities, including 
pharmacies, mobile vans, or fixed sites. The cost-effectiveness analysis focused on three 
settings in the UK: Bristol, Dundee and Walsall. These settings were selected based on 
differences in HCV prevalence, access to intervention coverage data, and feasibility of 
conducting a cost-effectiveness analysis.  Table 1 summarises key attributes of these settings. 
The chronic prevalence of HCV in the three settings (18-45%) ranges across the UK average of 
40%[3]. Coverage of harm reduction interventions varies from 72-81% for opioid substitution 
therapy (OST) and 30-57% for high coverage needle and syringe provision (HCNSP, taken to 
be at least one clean needle for every injection) compared with an average of 65% for OST 
and 48%-77% for HCNSP across UK[3, 25]. Although data is limited, PWID size estimates across 
our cities (750-2295) suggest they have moderate sized injecting populations[26, 27].  
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We collected cost data from NSP in each area. We only considered needle and syringe 
distribution to people who inject psychoactive drugs (such as opioids and stimulants; now 
denoted as PWID), not those injecting image and performance-enhancing drugs (IPEDs), as 
they have greater risk of HCV infection[28]. Other services provided by NSPs were not 
considered, including HCV testing, condom provision, and referral to community drug 
treatment programmes. In addition, we do not consider the impact of NSPs on HIV 
transmission.  
[Insert Table 1] 
Estimation of Costs 
The cost-effectiveness analysis uses a UK NHS (health and social care provider) 
perspective[29]. We estimated the incremental economic cost of NSP provision in each area 
for 2013-2014[30] in 2014 pounds sterling (GBP).  Cost data collection took place between 
March 2014 and July 2015 at several sites in each city, including the fixed-site NSP, two 
randomly selected pharmacy-based NSPs, and any additional NSP modalities operating in the 
area. Costs were estimated for the 2013-14 financial year. We took a bottom-up approach in 
collecting cost data, first estimating resource use and then valuing those resources according 
to their opportunity cost[31].  Resource use was measured using direct observation and 
reviewing programme records. We incorporated all resources: staff salaries, training, 
equipment, supplies, utilities, and building costs. Current market prices (2014 GBP) were 
applied to all resources; we estimated a ‘shadow cost’ for volunteer time or subsidized 
equipment. Overhead and support costs were estimated from programme records, and a 
portion allocated to NSP provision based on building space and management/support time. 
Human resource use was estimated through interviews and direct observations. Research 
costs were not included. All interviewees provided written consent, and the study received 
ethical approval by the London School of Hygiene and Tropical Medicine Research Ethics 
Committee (Reference: 6527). 
Cost inputs were defined as fixed costs (do not vary with output) and variable costs (vary with 
the level of output). Total costs for 2014 were estimated including all NSP modalities in each 
area, using their total fixed costs, plus an average variable cost for sterile injecting equipment 
(estimated per needle distributed to PWID).   
The costs of HCV care for HCV-related disease came from published estimates for the UK 
(Table S1)[32, 33], inflated to 2014 prices[34]. We assumed HCV treatment delivery costs for 
people currently injecting were 20% higher than for ex-injectors (extra nurse time)[35], and 
assumed treatment with 12-week direct acting antiviral (DAA) regimens after 2016[36] at a 
total drug cost of £39,600[37](Table S1). We assumed an annual cost for OST[38]. 
Model Description for Estimating Impact and Cost-effectiveness 
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A dynamic model of HCV transmission and treatment was developed to estimate the impact 
of needle and syringe distribution in each city; described elsewhere[10] and in the 
supplementary materials. Briefly, the model incorporates HCV transmission among PWID and 
disease progression in PWID and ex-injectors. The model is a deterministic compartmental 
model using ordinary differential equations, stratified by injecting duration, intervention 
status (OST and/or NSP, or not), risk status (homeless and/or crack injecting or not), currently 
injecting or not, infection status and disease stage. New initiates to injecting are initially 
susceptible to HCV and become infected at a per-capita rate depending on their intervention 
state, injecting duration category, risk category and prevalence of HCV infection in the 
population.  Risk, whether increased (injecting duration and high-risk categories) or 
decreased (if on OST and HCNSP), is assumed to apply both to HCV transmission and 
acquisition. We assume random mixing between all subgroups. The model includes HCV 
disease progression (Fig 1)[39]. Following successful treatment (sustained viral response), 
continued slower progression occurs among those with compensated cirrhosis or more 
severe disease[40-42].  We account for re-infection amongst PWID and re-treatment.      
 
[Insert Figure1] 
 
Model parameterisation and calibration 
Epidemiological, demographic and harm reduction related parameters common to both the 
intervention and counterfactual scenarios for all three cities are in Table S2.  The model was 
further parameterized for each city using context-specific survey data and data from the 
literature, and calibrated using intervention coverage and HCV prevalence data in three steps.  
Firstly, the model was calibrated to PWID population size estimates using a PWID 
demographic sub-model without infection by varying the numbers initiating injecting each 
year and cessation rates. Secondly, the coverage of HCNSP and OST were fitted using a sub-
model that includes HCV transmission but no disease progression (allowing recruitment rates 
onto HCNSP and OST to vary). Thirdly, the HCV prevalence was fitted using the full model with 
disease progression by varying the transmission rate for those with no increased or decreased 
risk (see supplementary information for more details). Additional HCV prevalence and 
incidence data were used to validate the model projections (Tables S2, S3 and Fig S1).  Based 
on a recent pooled analysis of UK and Australian data, currently being on HCNSP or OST were 
assumed to reduce the risk of HCV transmission by 41% and 59%, respectively[30], with the 
risk reduced multiplicatively for those on OST with HCNSP.  Service data on the number of 
needles and syringes distributed in 2014 were used to estimate the proportion of injections 
utilising sterile injecting equipment (coverage) per PWID in each area to proxy the proportion 
of PWID on HCNSP. Survey data was used to estimate the proportion of PWID currently on 
OST.  
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The model was used to estimate the number of new infections and person-years spent in each 
HCV disease stage. Quality adjusted life year (QALY) utility weights came from the literature 
(Table S3)[32, 33], with the baseline quality of life for PWID being lower (0.85) than for other 
individuals (0.94)[33].  
For 2014, the model directly used the total estimated area-level costs of NSP. For other years, 
total annual costs were adjusted for changes in the number of PWID while assuming the same 
NSP cost (inflation adjusted) and coverage. Costs of HCV care and treatment were attached 
to each HCV disease stage. We assumed that half of all mild or moderate patients are 
diagnosed[3] and incur a cost, whereas all individuals in more progressed disease stages 
incurred care costs. All costs and QALYs were discounted at 3.5% per year[29]. 
To reflect parameter uncertainty, distributions were assigned to many model and cost 
parameters, which were randomly sampled to obtain 1000 model fits (see supplementary 
materials). 
Cost-effectiveness analysis 
For the NSP intervention scenario we assumed the coverage of HCNSP remained stable for 50 
years (2016-2065). In contrast, the counterfactual scenario (‘no NSP’) removed the costs and 
benefits of HCNSP for 10-years (2016-2025), and then re-instated them for 40 years (2026-
2065) to capture the future effects of the lack of HCNSP on HCV transmission and disease 
morbidity. A time-horizon of 50 years is standard practice to consider the lifetime of 
individuals impacted by the intervention and to fully capture the effects of HCV disease 
progression[29]. The incremental costs, disease outcomes and QALYs of NSPs compared to 
‘no NSPs’ were estimated over 2016-2065 for all 1000 model fits. Mean incremental cost 
effectiveness ratios (ICER=incremental costs/incremental effects) were compared to the 
£20,000 per QALY willingness-to-pay (WTP) threshold recommended by NICE[43].  Mean net 
monetary benefit (NMB = (incremental effectiveness*WTP threshold)-incremental costs) was 
also estimated for each area. Cost-effectiveness acceptability curves were plotted to 
determine the proportion of simulations that are cost-effective at the WTP threshold.   
Sensitivity analysis 
We carried out multiple sensitivity analyses to test the impact of assumptions on the ICER. 
These included assuming: no diagnosis for pre-cirrhotic chronic HCV disease (50% diagnosed 
in main analysis); same HCV treatment cost for people currently and no longer injecting 
(increased cost for people currently injecting in main analysis); 0% discount rate for costs and 
QALYs (3.5% in main analysis) and increased time-horizon of 100 years (50 years in main 
analysis). A threshold analysis also considered the minimum time-horizon over which NSP are 
cost-effective at a WTP threshold of £20,000 per QALY. To assess the likely impact of the 
changing landscape of HCV treatment we conducted analyses assuming 50% or 75% lower 
cost of HCV treatment from 2016; doubling and quadrupling the low HCV treatment rates in 
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Bristol and Walsall from 2016 (Dundee already has a high treatment rate); and quadrupling 
the treatment rates in Bristol and Walsall from 2016 while also reducing HCV treatment costs 
by 75%.   
A linear regression analysis of covariance [44] was undertaken to determine which parameter 
uncertainties contributed most to variability in incremental costs and QALYs.  
 
RESULTS 
Cost Analysis for NSP 
The size and cost of NSPs varied across the areas (Table 2), as did the number of needles 
distributed per PWID (Tables S4, S5).  Although the annual fixed costs of NSPs varied (£35,983-
£49,143 in Bristol to £8,672-£11,807 in Dundee), the average variable cost of injecting 
equipment was more consistent (median £0.26/needle in Bristol; £0.78/needle in Dundee). 
Overall, total estimated costs for 2014 range from a median of £79.45/PWID in Walsall to 
£159.21/PWID in Dundee. Uncertainty in NSP costs were largely driven by assumptions on 
the wastage of injecting equipment (Fig S2).  
[Insert Table2] 
 
Impact projections for NSP 
Compared to the counterfactual of no NSP over the next 10 years, projections suggest a 
median of 84-199 infections (8% of infections in Bristol and Walsall, 40% in Dundee) and 2-20 
deaths (1% of deaths in each area) would be averted in each area by continuing provision of 
NSP over this period, with benefits tracked over a further 40 years. Area-level differences in 
infections averted are due to variations in HCV treatment coverage (greater in Dundee), with 
wide uncertainty around the impact projections for each area being due to uncertainty in 
many model parameters, as discussed later.  Despite this uncertainty, all simulations 
projected deaths and infections averted for the NSP intervention scenario(Table S6).  
 
Cost-effectiveness analysis 
In all three settings, over the 50-year time-horizon, healthcare and treatment costs are lower 
in the baseline NSP scenario than in the no NSP counterfactual scenario (Table S7). Overall, 
the NSP scenario is cost saving in Bristol and Dundee, saving an average of £159,712 in Bristol 
and £2.5 million in Dundee over 50-years and gaining 502 and 195 incremental QALYs, 
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respectively (Table 3). In Walsall, the mean incremental cost of the NSP scenario is £114,442 
and gains 192 incremental QALYs (ICER £596 per QALY gained). Using a willingness-to-pay 
(WTP) threshold of £20,000 per QALY gained[29], this represents a NMB of £10.2 million in 
Bristol, £6.4 million in Dundee and £3.7 million in Walsall over 50 years.    
 
[Insert Table3] 
 
In each city, all simulations suggest the NSP scenario gains QALYs compared with the no NSP 
scenario.  In Dundee, most simulations (78%) suggest that NSP is cost saving; for Bristol and 
Walsall, 46% and 40% of simulations respectively are cost saving (Fig 2 and S3). Over 90% of 
simulations for each area are below the WTP threshold of £20,000 per QALY saved(Fig 2).   
 
[Insert Figure 2] 
 
Sensitivity analysis 
The sensitivity analyses indicated that our cost-effectiveness projections are robust to 
variations in parameter assumptions (Fig 3). Increasing the time-horizon to 100 years made 
the NSP scenario cost saving in all three cities, as did reducing the discount rate to 0% (costs 
and QALYs). The threshold analysis revealed that NSP becomes cost-effective in Bristol and 
Walsall if the time horizon is longer than 2- or 6-years post-intervention, respectively, while 
in Dundee it is cost-saving even with no years of follow-up. 
The highest ICERs for all three settings occurred when the cost of HCV treatment was reduced 
by 75% (Bristol and Walsall: £1518 and £2812 per QALY respectively, Dundee still cost-saving), 
but the mean ICERs remained well below the WTP threshold. Quadrupling the treatment rate 
improved the NSP ICER because of an added prevention benefit in terms of reducing re-
infections after successful HCV treatment (All three are cost-saving).   
 
[Insert Figure 3]  
 
Analysis of covariance (Fig S4) suggests that most of the variability in the incremental costs 
and QALYs in each setting is due to uncertainty in the efficacy of HCNSP (accounting for 52%, 
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50% and 27% of the variability in incremental costs and 80%, 73% and 20% of variability in 
incremental QALYs in Bristol, Walsall, and Dundee, respectively). The more effective HCNSP 
is at reducing HCV transmission the lower the incremental costs and higher the incremental 
QALYS (see Fig S5 for Bristol example). In Dundee, uncertainty in the prevalence of HCV also 
caused considerable variability (57% for incremental costs and 61% for incremental QALYs). 
A higher initial HCV prevalence results in lower incremental costs and higher incremental 
QALYS resulting in NSP being more cost-effective(see Fig S5). Otherwise, uncertainty in the 
cost of injecting equipment in Bristol and Walsall was an important cause of variability in 
incremental costs (10% and 28% respectively), while uncertainty in the coverage of HCNSP 
was an important cause of variability in the incremental QALYs for Bristol and Walsall (9% and 
5% respectively). 
 
DISCUSSION 
Main Findings 
Our analyses suggest that NSPs are highly cost-effective in the UK, and in some settings cost-
saving. We found variation in NSP costs across the three areas; there is no ‘standard’ structure 
for NSP services in the UK, and as such, each area had different service modalities and 
organisational structures. Differences in cost-effectiveness were also driven by variations in 
the impact achieved; fewest deaths were averted in Walsall due to its lower HCV 
prevalence[10], whilst more deaths and infections were averted in Bristol due to the higher 
HCV prevalence and larger PWID population. The largest proportion of infections averted was 
in Dundee where there is higher coverage of HCV treatment with HCNSP preventing re-
infection.  These differences did not affect our finding that NSPs are highly cost-effective. Our 
results were also robust to varied assumptions, including a lower cost for HCV treatment and 
a scale-up in HCV treatment, both of which are likely to occur in the near future.  
Comparison with Existing Evidence 
This is the first study evaluating the cost-effectiveness of NSPs in western Europe, and the 
first ever study to use empirical estimates of the efficacy of NSP for reducing HCV transmission 
risk[9]. Two other studies have considered the cost-effectiveness of NSP for averting HCV 
transmission; a study from Baltimore[22] estimated a cost of several hundred thousand 
dollars per averted HCV infection, and an Australian study indicated that  NSPs are cost-saving 
in preventing HIV and HCV infection due to averted healthcare costs[23]. Unfortunately, it is 
difficult to compare these findings to our projections. The US study did not collect primary 
cost data, but assumed a cost of US$5 per NSP client per day, contrasting with our estimates 
of £0.16-£0.42 per PWID per day.  The results of the Australian analysis were driven by the 
reduction in HIV transmission, which we did not include in our analysis.  
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Strengths and Limitations 
A strength of our analysis lies in our use of primary cost data to reflect the ‘real-world’ costs 
of implementing NSPs in the UK. Although this ensures their relevance to the UK, 
uncertainties still existed due to gaps in the data. This was especially true for pharmacy-based 
NSP services, where detailed records were not available. These uncertainties in the cost of 
NSPs were included in our projections, and our findings were robust (i.e. were all cost-
effective) despite this. Standardised reporting of number of visits and numbers of needles 
and syringes distributed would facilitate comparison across different NSP sites, while 
implementing a system to record the number of individual clients reached would greatly 
facilitate estimation of unit costs and intervention coverage.   
A second potential weakness is that the assessment of health impact is based on model 
projections rather than study outcomes, and so caution is advised in the interpretation of our 
cost-effectiveness findings. This is common to all NSP evaluations, with our study improving 
on previous analyses by using empirical effect estimates for how NSP reduces HCV 
transmission risk rather than relying on self-reported behaviour change. We incorporated 
uncertainty in these empirical effect estimates in our analysis, as well as other parameters, 
which contributed to the large variation in both incremental costs and QALYs.  Uncertainty in 
the HCV prevalence in Dundee also contributed to the variation in incremental costs and 
QALYs in that setting. Despite this uncertainty, our results were robust, with over 90% of 
simulations under the UK willingness-to-pay threshold of £20,000 per QALY.  
Thirdly, there was uncertainty in the NSP coverage for each area. We used conservative 
service provision estimates of NSP coverage, which were lower or comparable to survey 
estimates from each setting, and also included uncertainty around these coverage estimates. 
More accurate estimates of syringe coverage are needed, as is consistent monitoring of NSPs 
and the services they provide[12]. 
Our approach to estimating the cost-effectiveness of NSPs was highly conservative: we did 
not incorporate other potential health benefits of NSP, or impact on people injecting IPEDs. 
We did not incorporate the health benefits associated with NSPs reducing the risk of HIV 
acquisition[45] because of difficulty in reliably modeling the transmission of an infection that 
is at low-levels. Incorporating HIV infections averted would improve our cost-effectiveness 
estimates[15, 46]. The analysis also did not include the health benefits from reducing 
injection-site infections and injuries [47], which may result through engaging the client in 
discussions about safer injecting behaviour. Our analysis also did not reflect the potential 
impact of NSPs in addressing the complex mental health and social support issues that PWID 
experience[48, 49]. When considering other potential benefits of NSPs, such as preventing 
HIV infection or skin and soft tissue infections, and addressing the psychosocial and welfare 
needs of PWID, NSPs are likely to be highly cost-saving. 
Implications and conclusions 
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NSP services are a highly effective low cost intervention to reduce HCV transmission, and in 
some settings are cost-saving. For example, in Dundee, we estimate long-term savings of up 
to 250% of the initial investment. In a recent analysis of public health interventions 
considered by NICE between 2006 and 2010, only 15% were cost-saving[50]. In this context, 
NSPs can be considered a very strong investment choice. 
These findings clearly point to the need to maintain funding for NSP services in the UK and 
elsewhere – while at the same time emphasising the need to strengthen the evidence for 
their effectiveness, including how the level of NSP provision and other NSP characteristics 
affect its efficacy.  Further work should also investigate what strategies or factors improve the 
cost-effectiveness of NSP and what can aid its scale-up. The findings also highlight the 
importance of joint commissioning and decision-making between agencies in the UK to meet 
the needs of local populations. Due to recent NHS reforms, the agencies responsible for 
commissioning NSPs are often different from those incurring any cost-savings. A co-financing 
approach would better represent the overall societal benefits of such an investment[51]. 
Different agencies may also need outcomes on different time frames; a lifetime horizon is 
recommended in NICE guidance for economic evaluations, while policy-makers and funders 
are more concerned with short-term outcomes. We found that shorter time-horizons 
remained cost-effective in Bristol and Walsall (after 2- and 6-years of follow-up), and cost-
saving in Dundee.  Short-term returns may also be accrued through psychosocial and welfare 
benefits of NSPs as mentioned above.   
These findings, whilst having limited generalisability for low and middle-income countries, are 
likely to be highly generalisable to other high-income settings with comparable HCV 
prevalence and harm reduction coverage such as Australasia and Western Europe[52], and 
therefore support the recommendations of WHO to develop and implement policies to 
support harm reduction among PWID[53]. These interventions should be delivered in 
combination with and complemented by prioritisation of drug treatment and expansion of 
HCV and HIV treatment[24].   
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Fig 1 Disease progression model 
 
 
 
F0-F4 are Metavir liver disease stages, with F0-F1 being mild disease, F2-F3 being moderate 
disease and F4 being compensated cirrhosis. Progression through the disease states occurs at 
a rate determined by the current disease state, as are the disease related death rates.  All 
states have a cessation rate from injecting drug use and a non-disease related background 
death rate.  Infection can occur from all disease states but are not shown for clarity. Those 
who spontaneously clear the infection are assumed to remain in the susceptible category. 
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Table 1 Coverage of OST and NSP and epidemiology of HCV among PWID in each city in 2014 
Baseline Characteristics  Bristol Dundee Walsall 
PWID population size (2011) 2295 (2025-2564) a 750 (675-825) b 1460 (1296-1623) c 
Total adult population size (aged 15-
59)[54] 
286,000 99,000 170,898 
Prevalence of current injecting drug 
use in adult population (%) 
0.8 0.75 0.85 
Chronic HCV Prevalence in PWID 
population 
45% (40-50%) d 26% (19-32%) e 18% (11-26%) d 
Proportion of PWID on OST 81% (77-86%) f 73% (65-79%) e 72% (61-82%) d 
Proportion of PWID with HCNSP (from 
service provision calculation) 
57% (38-82%) d 49% (34-79%) e 30% (21-42%) d 
Number PWID treated for HCV per 
year 
18 g 40 h 2 i 
a adjusted from [26]; b local estimate adjusted from [27]; c unpublished PWID prevalence for West 
Midlands; d Data extracted from unlinked anonymous monitoring survey [4]; e data extracted from 
Needle Exchange Surveillance Initiative [55]; f Mills, 2012 [56]; g Martin, 2015 [57]; h from 2015, 
personal communication John Dillon (Professor of Hepatology and Gastroenterology); i assumed 
similar rate per infected PWID as Bristol as conservative estimate; HCNSP high coverage needle and 
syringe provision; PWID people who inject drugs; OST, opioid substitution therapy; HCV, hepatitis C 
virus 
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Table 2 NSP related costs for PWID by city in 2014 GBP: Inputs for the model  
  
Total Needles distributed 
Total Annual 
Fixed Costs 
Average Variable 
Cost per Needle 
Total Annual Cost 
 
City Median Min Max Median Min Max Median Min Max Median Min Max 
Bristol 820,593 786,540 844,650 £44,142 £35,983 £49,143 £0.26 £0.15 £0.41 £262,762 £147,761 £391,409 
Dundee 142,098 138,250 145,770 £10,159 £8,672 £11,807 £0.78 £0.37 £1.19 £120,797 £62,123 £180,050 
Walsall 231,457 225,270 237,110 £21,068 £16,321 £26,319 £0.45 £0.20 £1.03 £110,715 £66,667 £153,667 
(for more information on derivation see supplementary information and [30]); NSP, needle 
and syringe provision; PWID, people who inject drugs. 
  
Table 3 Cost-effectiveness results: average total costs (2014 GBP), QALYs and incremental 
effectiveness ratios for the baseline NSP scenario compared with the no NSP scenario over 50 
years  
 
Total Cost Incremental 
Cost 
Total 
QALYs 
Incremental 
QALYs 
Mean ICER NMB 
Bristol 
      
no NSP £304,157,179 
 
187,663 
   
NSP £303,997,467 -£159,712 188,165 502 dominant £ 10,201,117 
Dundee 
      
no NSP £94,951,896 
 
83,904 
   
NSP £92,455,470 -£2,496,426 84,099 195 dominant £ 6,390,222 
Walsall 
      
no NSP £153,697,867 
 
142,702 
   
NSP £153,812,309 £114,442 142,894 192 £596 £   3,722,890 
QALY, quality adjusted life year; ICER, incremental cost effectiveness ratio; NMB, net 
monetary benefit; NSP, needle and syringe programmes. 
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Figure 2 Cost-effectiveness acceptability curves for each city 
 
Fig 3 Univariate Sensitivity Analysis 
Bristol 
 
Dundee 
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Walsall 
 
ICER, incremental cost effectiveness ratio; QALY, quality adjusted life year 
 
Supporting Information 
S1 Appendix. Technical Supplement 
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Supplementary Material 
Evaluating the cost-effectiveness of needle and syringe programmes in preventing Hepatitis C 
transmission in people who inject drugs 
METHODS 
ESTIMATION OF COSTS 
DATA COLLECTION  
Data collected incorporates the costs for different modalities of NSP provision (pharmacy, 
specialised and mobile sites) within each city. Each area provided a different range of modalities.  In 
Bristol, one fixed site NSP which also provided outreach and sub-contracted NSP services to 25 
pharmacies.  In Dundee, there was one fixed-site NSP and five pharmacies overseen by a team of 
specialist nurses.  Finally, in Walsall there was one fixed-site NSP which sub-contracted to 12 
pharmacies, 1 out-of-hours pharmacy, and one drop-in centre. In total, we collected cost data for 
three fixed sites (one per city), six pharmacies (two per city), and three ‘other’ modalities (including 
mobile outreach, out-of-hours pharmacy services, and a drop-in centre), which could potentially 
enable scale-up of output and coverage levels.  Only a sub-sample of pharmacies was costed in detail 
due to time and cost limitations for the study. The costs of remaining pharmacies in each area were 
estimated using their output data and unit cost data from the pharmacies where detailed costings 
were undertaken to give an overall cost estimate per area.   
The cost analysis covers a period of one financial year (2013-14), the most recent for which data was 
fully available, and takes a provider perspective.  We estimated the total and unit economic costs for 
distributing clean needles to people who inject drugs.  Our approach to costing was incremental to 
existing services, and was focused on needle and syringe exchange.  We took an ingredients-based 
approach in costing, first estimating the resources used in delivering NSP services and then applying 
current market prices (2014 pounds sterling) to all resources in order to estimate a cost.  Where the 
market price did not accurately reflect the value of resources (for example volunteer time), we 
estimate a ‘shadow cost’ based on equivalent salary rates for the position in question (1, 2).  
Overhead and support costs were estimated from programme records, and a portion allocated to 
NSP services.   
In collecting resource use data, where possible, data were extracted from existing reporting 
mechanisms including budget and expenditure records, human resources records and the 
management information system.  In addition, we carried out direct observations of staff time and 
activities in order to confirm supply use estimates, and allocate resources which are shared between 
the NSP and other harm reduction services (such as staff time, building space, equipment or vehicle 
operation).  Shared resources were allocated to services as a proportion of total services delivered 
and total time spent on each service.  Data were collated in a standardized MS Excel spreadsheet.  
Data collection was primarily conducted by one researcher, and quality-controlled by a second 
researcher. 
Due to the nature of pharmacy-based needle exchange, there was far less detailed output data 
available within pharmacies.  We therefore took a number of assumptions in estimating the outputs 
at pharmacies.  The type of data available for pharmacy-based needle distribution in each city 
varied; in Bristol pharmacies reported on the total number of visits, while in Dundee pharmacies 
reported on both the number of visits and the total number of needles distributed.  Walsall 
pharmacies reported on the number of packs distributed. Based on feedback both from pharmacies 
and fixed sites, we assumed that 100% of clients obtaining needles at pharmacies were opiate users, 
and that users of image and performance-enhancing drugs (IPEDs) did not access NSPs at 
pharmacies. We conducted observations of transactions at six pharmacies, and from these 
observations assumed that pharmacies distributed an average of 1.12 needle packs per transaction.  
The out-of-hours pharmacy had begun distribution of ‘one-hit kits’ shortly before the data collection 
period; as there was very little information on the quantity of ‘one-hit kits’ distributed per visit, we 
varied our assumption of ‘one-hit kit’ distribution as between 1 and 10 kits per visit – this was drawn 
from the minimum and maximum quantities distributed per visit in the two weeks prior to the site 
visit.  
DATA ANALYSIS 
Fixed and Variable costs 
Costs at all sites were classified as fixed and variable costs to facilitate analysis.  Fixed costs are 
defined as those costs which are not easily changed in the short-term.  Fixed costs included the 
following ingredients: 
• Overhead costs for pharmacy/ fixed site management, estimated as the percentage of needle 
exchange services delivered, as compared to other services delivered in the pharmacy/ in the 
local area. 
• Coordination by commissioners, included as overhead and allocated to the site as the 
percentage of needle exchange services delivered, as compared to other services delivered in 
the pharmacy/ in the local area. 
• Training as a minimum includes awareness of the need for discretion, but this should also 
include an understanding of how to treat people in a non-judgemental way, and may include 
further education on common injecting practices and harm reduction messages.  Training 
costs were estimated using an ingredients-based approach  
• Health and safety training, included as a cost for fixed site staff but not for pharmacists, who 
as a part of their normal job, will already have received health and safety training (e.g. needle 
stick injuries) and received hepatitis B vaccines 
• Vehicle purchase, estimated using an ingredients approach, and allocated as the proportion 
of mileage used for NSP services as compared to other services. 
Variable costs are those costs which vary depending on the volume of services provided, and can 
change in the short-term.  Variable costs included in the analysis are: 
• Injecting equipment in pre-made packs or “pick ‘n’ mix” as appropriate to the site/service.  
Equipment and paraphernalia distributed varied between pharmacies and fixed sites and from 
site to site.  Equipment distributed includes: pots, water, citric acid, needles/syringes (various 
types and sized), condoms, sharps bins.  The cost of this equipment will be estimated using a 
combination of the ingredients-based approach and step-down accounting.  For pharmacies 
distributing needle packs, the base case analysis assumes that packs of 10 are routinely 
distributed.  This is varied to packs of 20 needles in the sensitivity analysis.   
• Staff time costs including service and administrative staff, allocated to NSP services as a 
percentage of their time use for NSP services as compared to other services, using a 
combination of observational and interview data 
• Waste management and disposal of returned needles.    
• Vehicle fuel, insurance and maintenance costs, estimated using an ingredients approach, and 
allocated as the proportion of mileage used for NSP services as compared to other services. 
Estimating city-level costs 
In order to input into the cost-effectiveness model, we estimated the total cost for distribution of 
needles to people injecting opiate and other non-IPED drugs in each of the three commissioning 
areas included in the study.  We take the assumption that IPED users are at reduced risk of hepatitis 
C infection via shared needles (3). This is based on low reported prevalence of hepatitis C within 
IPED users.   
Our estimate of total costs for distributing needles to non-IPED users is estimated using total fixed 
costs at the city level, plus a weighted average variable cost per needle distributed to opiate clients.  
This estimation approach is intended to proxy the equivalent costs of providing needles only to 
opiate users; it represents the full fixed cost of the infrastructure necessary to provide needle and 
syringe exchange and the variable cost attributable to non-IPED users. We anticipate this to be a 
conservative approach, which does not account for the benefit of distributing needles to IPED users.   
Total fixed cost at city level are estimated accounting for the fixed site in each city, as well as all 
pharmacies and other modalities operating in each city.  For pharmacies not included in our costing 
sample, we estimated an average fixed cost per pharmacy for each commissioning area using the 
two or three pharmacies sampled for detailed cost data collection.  We then applied an average 
fixed cost to all pharmacies across the commissioning area; this information was provided by fixed 
sites in each city. Most pharmacies were provided with a small incentive payment per transaction. 
Where incentive payments were less than or equal to the costs of staff time for transactions these 
were treated as a transfer, and not included as an additional cost.  Where incentive payments were 
greater than the costs of staff time, any additional amount was considered to be an additional cost 
and factored into the total cost estimate. 
Average variable costs per opiate needle distributed were estimated for each service modality in 
each city, and weighted to reflect the total proportion of opiate needles distributed through that 
service modality city-wide.  This weighted average variable cost was then applied to the total 
number of needles distributed city-wide to come to an estimate of the total city-wide variable cost.    
In order to understand the impact of uncertainty encountered in collecting NSP costs in the cost-
effectiveness model, we conducted a univariate sensitivity analysis. We included factors in the 
sensitivity analysis which could not be directly observed, or which varied substantially between sites 
– including supply wastage, staff time taken for needle distribution, volunteer salaries, equipment 
wastage, opiate/IPED client mix, number of needles distributed per visit, and discount rate. The 
results from this sensitivity analysis are presented in Supplementary Figure 2.  Parameters with the 
greatest impact on cost at a city level included assumptions surrounding supplies/equipment 
wastage and personnel time.  Reducing estimated supplies/equipment cost by 50% resulted in an 
average of 26% reduction in city-level costs, while increasing equipment costs to 200% of that 
observed increased city-level costs by an average of 52%.  Reducing staff costs by 50% reduced total 
city-level costs by an average of 8%, while increasing staff costs to 200% increased total city-level 
costs by an average of 17%. 
TABLE S1 HEALTH RELATED COSTS AND QALY WEIGHTS ASSOCIATED WITH DIFFERENT STAGES OF DISEASE 
PROGRESSION 
 Value £ Distribution Source 
Annual Costs    
OST (specialist prescribing) 2,839.28 Gamma (4) 
Uninfected 0.00 Constant (5) 
F0 and F1 Mild HCV  187.59 Gamma(0.659,289) (5) 
F2 and F3 Moderate HCV  974.68 Gamma(0.485,2038) (5) 
Compensated Cirrhosis  1,546.98 Gamma(0.211,7452) (5) 
Decompensated cirrhosis 12,397.57 Gamma(0.901,13974) (5) 
Hepatocellular Carcinoma 11,170.04 Gamma(0.926,12251) (5) 
Liver transplant 40,273.00 PPIxGamma(89.75,304.5) (6) 
Post-transplant 2,041.00 PPIxGamma(15.22,91.1) (6) 
Hospital costs year of transplant 13,937.00 PPIxGamma(13.78,686.4) (6) 
Treatment    
sofosbuvir + ledipasvir – PWID 48,816.00 Constant (6) 
sofosbuvir + ledipasvir - ex/non-PWID 40,680.00 Constant (6) 
Liver-related death 0.00 Constant  assumption 
    
QALY Weights    
Uninfected    
Ex / non-PWID 0.94 Constant (6) 
PWID 0.85 Uniform (0.8, 0.9) (6) 
Mild HCV    
Without Treatment (F0 and F1) 0.77 Beta (521.2375,155.6943) (6) 
SVR (F1 only) 0.82 Beta (65.8678,14.4588) (6) 
Moderate HCV (F2 and F3)   (6) 
Without Treatment 0.66 Beta (168.2461, 86.6723) (6) 
SVR 0.72 Beta (58.0608,22.592) (6) 
Compensated Cirrhosis     
Without Treatment 0.55 Beta (47.1021, 38.5381) (6) 
SVR 0.61 Beta (58.0608,37.1124) (6) 
Decompensated cirrhosis 0.45 Beta (123.75, 151.25) (6) 
Hepatocellular Carcinoma 0.45 Beta (123.75, 151.25) (6) 
Liver transplant 0.45 Beta (123.75, 151.25) (6) 
Post-transplant 0.67 Beta (59.2548, 29.1852) (6) 
Liver-related death 0  (6) 
PPI =Hospital and Community Health Services Pay and Price Index Inflation 2003/04 to 2014/2015 (1.47).  QALY  
(quality adjusted life year) 
 
MODEL DESCRIPTION FOR ESTIMATING IMPACT AND COST-EFFECTIVENESS 
Stratifications by injecting duration are included to incorporate increased injecting cessation and 
HCV-acquisition risk among people recently initiated into injecting(7-9), with the chosen category in 
line with reporting from the unlinked anonymous monitoring (UAM) survey of PWID (10). PWID are 
also stratified into different intervention states that influence HCV transmission risk: no intervention, 
OST only, HCNSP only, or both. PWID enter the model as recent initiates with no intervention 
coverage. They transition through successive injecting duration categories with rates of injecting 
cessation and non-HCV related death. Due to a lack of data, we assumed recruitment and leaving 
rates onto and off OST and HCNSP were independent of the current intervention state; previous 
modelling suggests this should not affect our model projections(11). The model is further stratified 
by high and low HCV transmission risk, with a proportion starting injecting in the high-risk 
category(12) and PWID transitioning between these categories. PWID were defined as high-risk if 
they had been homeless in the last year and/or injected crack in last 4 weeks (low-risk otherwise), 
which was associated with increased HCV transmission risk(13).   
 
New initiates into injecting are initially susceptible to HCV, and become infected at a per-capita rate 
depending on their intervention state, injecting duration category, risk category, and prevalence of 
HCV infection in the population. Previous analyses suggest incorporating like-with-like mixing 
(individuals with the same risk behaviour or characteristics being more likely to form injecting 
contacts with each other than with other individuals) will have little effect on our model 
projections(11), with data suggesting it only occurs weakly in Bristol(14), and so random mixing was 
assumed between all sub-groups.   
 
Once infected, some PWID spontaneously clear infection(15), with the remainder becoming 
chronically infected, which is life-long unless treated. Chronically infected PWID progress through 
disease states (Figure 1c) with HCV disease-related death occurring from the decompensated 
cirrhosis, hepatocellular carcinoma, liver transplant and post-liver transplant stages.  
 
HCV treatment is only allowed in the F0-F3 and compensated cirrhosis states as it is unclear whether 
treatment in later disease stages is beneficial(16).  An annual number of PWID are treated, with a 
proportion achieving a sustained virological response (SVR-effective cure) and the remainder 
returning to their prior infection category. Following successful treatment, no further disease 
progression occurs in the F0-F3 states(17, 18), but continued slower progression occurs among those 
with compensated cirrhosis(18, 19).  We allow re-infection of those who have attained SVR, and re-
treatment of those who fail treatment or become re-infected in line with current 
recommendations(20).  
 
MODEL EQUATIONS 
𝑆𝑆𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚 and 𝐶𝐶𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚 are the number of susceptible and chronically infected individuals in the model, 
where 𝑖𝑖 = 0,1 for off OST and on OST respectively, 𝑗𝑗 = 0,1 for <100% NSP and >100% NSP 
respectively, 𝑛𝑛 = 1,2,3,4 for recent and non-recent or long-term injectors and ex PWID, 𝑚𝑚 = 𝑙𝑙,ℎ for 
low and high risk respectively and 𝑘𝑘 = 1,2 … 9 for the disease progression states chronic infected 
(F0, F1, F2, F3), compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver 
transplant and post liver transplant respectively.    
The ordinary differential equation model is made up of 450 equations which are described below in 
sections for different aspects of the model. 
Inflow of injectors 
There are only two variables in the model which allow an inflow of new injectors. These are low and 
high-risk susceptible individuals in the first disease progression category with no intervention: the 
number of new low risk individuals per year is 𝜃𝜃(1 − 𝜙𝜙) and the number of new high-risk individuals 
per year is 𝜃𝜃𝜙𝜙. 
Injecting duration progression 
These terms in the equations are concerned with movement from one injecting duration category to 
another as well as PWID related and background mortality.  𝐼𝐼𝐷𝐷𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚 denotes the terms in an ordinary 
differential equation of injecting duration category 𝑛𝑛.  It occurs for all values of 𝑚𝑚, 𝑖𝑖, 𝑗𝑗,𝑘𝑘.  𝑌𝑌𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚 is 
used to describe one of the variables in the model, where 𝑌𝑌 = 𝑆𝑆 or 𝐶𝐶 and the subscripts and 
superscripts are as described previously.  The leaving rate, 𝜇𝜇𝑖𝑖 = 𝜔𝜔𝑖𝑖 + 𝜈𝜈𝑖𝑖, where 𝜔𝜔𝑖𝑖 is the cessation 
rate and 𝜈𝜈𝑖𝑖 is the death rate for injecting duration 𝑖𝑖.  
�𝐼𝐼𝐷𝐷𝑖𝑖,𝑗𝑗,𝑘𝑘1,𝑚𝑚
𝐼𝐼𝐷𝐷𝑖𝑖,𝑗𝑗,𝑘𝑘2,𝑚𝑚
𝐼𝐼𝐷𝐷𝑖𝑖,𝑗𝑗,𝑘𝑘3,𝑚𝑚� = �
−𝜏𝜏1 − 𝜇𝜇1 0 0
𝜏𝜏1 −𝜏𝜏2 − 𝜇𝜇2 00 𝜏𝜏2 −𝜏𝜏3��
𝑌𝑌𝑖𝑖,𝑗𝑗,𝑘𝑘1,𝑚𝑚
𝑌𝑌𝑖𝑖,𝑗𝑗,𝑘𝑘2,𝑚𝑚
𝑌𝑌𝑖𝑖,𝑗𝑗,𝑘𝑘3,𝑚𝑚� 
When 𝑛𝑛 = 4 (ex PWID) the terms have a different form: 
𝐼𝐼𝐷𝐷𝑘𝑘
4 = � 𝜔𝜔1𝑌𝑌𝑖𝑖𝑗𝑗𝑘𝑘1,𝑚𝑚
𝑖𝑖,𝑗𝑗,𝑚𝑚 + � 𝜔𝜔2𝑌𝑌𝑖𝑖𝑗𝑗𝑘𝑘2,𝑚𝑚𝑖𝑖,𝑗𝑗,𝑘𝑘,𝑚𝑚 + � 𝜔𝜔3𝑌𝑌𝑖𝑖𝑗𝑗𝑘𝑘3,𝑚𝑚𝑖𝑖,𝑗𝑗,𝑘𝑘,𝑚𝑚 − 𝜈𝜈4𝑌𝑌𝑘𝑘4 
 
Interventions: OST and NSP 
These terms in the equations are concerned with movement of injectors from one intervention 
category to another.  𝐼𝐼𝑇𝑇𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚 denotes the terms in the ordinary differential equation of OST 
intervention category 𝑖𝑖 and NSP intervention category 𝑗𝑗.  The rates 𝜂𝜂 and 𝛽𝛽  are the recruitment 
rates onto NSP and OST respectively.  The rates 𝜅𝜅 and  𝛾𝛾  are the leaving rates of NSP and OST 
respectively. These terms can be found for all values of 𝑚𝑚,𝑘𝑘 and current injector categories but not 
the exPWID categories (𝑛𝑛 = 4) 
⎝
⎜
⎛
𝐼𝐼𝑇𝑇0,0,𝑘𝑘𝑛𝑛,𝑚𝑚
𝐼𝐼𝑇𝑇1,0,𝑘𝑘𝑛𝑛,𝑚𝑚
𝐼𝐼𝑇𝑇0,1,𝑘𝑘𝑛𝑛,𝑚𝑚
𝐼𝐼𝑇𝑇1,1,𝑘𝑘𝑛𝑛,𝑚𝑚⎠
⎟
⎞ = �−𝜂𝜂 − 𝛽𝛽 𝛾𝛾 𝜅𝜅 0𝛽𝛽 −𝛾𝛾 − 𝜂𝜂 0 𝜅𝜅𝜂𝜂 0 −𝜅𝜅 − 𝛽𝛽 𝛾𝛾0 𝜂𝜂 𝛽𝛽 −𝛾𝛾 − 𝜅𝜅�
⎝
⎜
⎛
𝑌𝑌0,0,𝑘𝑘𝑛𝑛,𝑚𝑚
𝑌𝑌1,0,𝑘𝑘𝑛𝑛,𝑚𝑚
𝑌𝑌0,1,𝑘𝑘𝑛𝑛,𝑚𝑚
𝑌𝑌1,1,𝑘𝑘𝑛𝑛,𝑚𝑚⎠
⎟
⎞
 
High and Low risk 
These terms in the equations are concerned with movement of current injectors between low and 
high risk. 𝐻𝐻𝑅𝑅𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚  denotes the terms in the ordinary differential equation of risk category 𝑚𝑚.  Here 𝜎𝜎 
is the initiation rate into high risk categories and 𝜁𝜁is the leaving rate. These terms can be found in 
the equations for all values of 𝑖𝑖, 𝑗𝑗,𝑘𝑘 and 𝑛𝑛 = 1,2,3. 
�
𝐻𝐻𝑅𝑅𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑙𝑙
𝐻𝐻𝑅𝑅𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,ℎ � = �−𝜎𝜎 𝜁𝜁𝜎𝜎 −𝜁𝜁��𝑌𝑌𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑙𝑙𝑌𝑌𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,ℎ � 
Disease progression 
These terms in the equations are concerned with movement through the disease states.  Infection 
and treatment are described separately.  𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚 denotes the terms in the ordinary differential 
equation of disease category 𝑘𝑘 for susceptible individuals and 𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚  for infected individuals.  Below 
is a description of the rates. 
Parameter description symbol 
Yearly progression rate from 
f0 to f1 
𝜌𝜌1 
Yearly progression rate from 
f1 to f2 
𝜌𝜌2 
Yearly progression rate from 
f2 to f3 
𝜌𝜌3 
Yearly progression rate from 
f3 to compensated cirrhosis 
𝜌𝜌4 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These terms can be found in the equations for all values of 𝑖𝑖, 𝑗𝑗,𝑛𝑛 and 𝑚𝑚.   
Yearly progression rate from 
compensated cirrhosis to 
decompensated cirrhosis 
𝜌𝜌5 
Yearly progression rate from 
compensated cirrhosis or 
decompensated cirrhosis to 
hepatocellular carcinoma  
𝜌𝜌6 
Yearly progression rate from 
decompensated cirrhosis or 
HCC to liver transplant 
𝜌𝜌7 
Yearly progression rate from 
liver transplant to post liver 
transplant 
𝜌𝜌8 
Decompensated cirrhosis 
related death rate per year 
𝑑𝑑6 
Hepatocellular carcinoma 
related death rate per year 
𝑑𝑑7 
Liver transplant related 
death rate per year 
𝑑𝑑8 
Post liver transplant related 
death rate per year 
𝑑𝑑6 
Relative risk for progression 
rate from  compensated to 
decompensated cirrhosis 
(𝜌𝜌5) following SVR 
𝑒𝑒5 
Relative risk for progression 
rate from compensated 
cirrhosis to HCC (𝜌𝜌6) 
following SVR 
𝑒𝑒6 
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⎜
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⎜
⎛
𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,1𝑛𝑛,𝑚𝑚
𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,2𝑛𝑛,𝑚𝑚
𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,3𝑛𝑛,𝑚𝑚
𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,4𝑛𝑛,𝑚𝑚
𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,5𝑛𝑛,𝑚𝑚
𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,6𝑛𝑛,𝑚𝑚
𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,7𝑛𝑛,𝑚𝑚
𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,8𝑛𝑛,𝑚𝑚
𝐷𝐷𝑆𝑆𝑖𝑖,𝑗𝑗,9𝑛𝑛,𝑚𝑚⎠
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0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 00 0 0 0 −𝑒𝑒5𝜌𝜌5 − 𝑒𝑒6𝜌𝜌6 0 0 0 00 0 0 0 𝑒𝑒5𝜌𝜌5 −𝜌𝜌6 − 𝜌𝜌7 − 𝑑𝑑6 0 0 00 0 0 0 𝑒𝑒6𝜌𝜌6 𝜌𝜌6 −𝜌𝜌7 − 𝑑𝑑7 0 00 0 0 0 0 𝜌𝜌7 𝜌𝜌7 −𝜌𝜌8 − 𝑑𝑑8 00 0 0 0 0 0 0 𝜌𝜌8 −𝑑𝑑9⎠⎟
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⎛
𝑆𝑆𝑖𝑖,𝑗𝑗,1𝑛𝑛,𝑚𝑚
𝑆𝑆𝑖𝑖,𝑗𝑗,2𝑛𝑛,𝑚𝑚
𝑆𝑆𝑖𝑖,𝑗𝑗,3𝑛𝑛,𝑚𝑚
𝑆𝑆𝑖𝑖,𝑗𝑗,4𝑛𝑛,𝑚𝑚
𝑆𝑆𝑖𝑖,𝑗𝑗,5𝑛𝑛,𝑚𝑚
𝑆𝑆𝑖𝑖,𝑗𝑗,6𝑛𝑛,𝑚𝑚
𝑆𝑆𝑖𝑖,𝑗𝑗,7𝑛𝑛,𝑚𝑚
𝑆𝑆𝑖𝑖,𝑗𝑗,8𝑛𝑛,𝑚𝑚
𝑆𝑆𝑖𝑖,𝑗𝑗,9𝑛𝑛,𝑚𝑚⎠
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⎜
⎜
⎜
⎜
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⎛
𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,1𝑛𝑛,𝑚𝑚
𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,2𝑛𝑛,𝑚𝑚
𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,3𝑛𝑛,𝑚𝑚
𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,4𝑛𝑛,𝑚𝑚
𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,5𝑛𝑛,𝑚𝑚
𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,6𝑛𝑛,𝑚𝑚
𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,7𝑛𝑛,𝑚𝑚
𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,8𝑛𝑛,𝑚𝑚
𝐷𝐷𝐶𝐶𝑖𝑖,𝑗𝑗,9𝑛𝑛,𝑚𝑚⎠
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−𝜌𝜌1 0 0 0 0 0 0 0 0
𝜌𝜌1 −𝜌𝜌2 0 0 0 0 0 0 00 𝜌𝜌2 −𝜌𝜌3 0 0 0 0 0 00 0 𝜌𝜌3 −𝜌𝜌4 0 0 0 0 00 0 0 𝜌𝜌4 −𝑒𝑒5𝜌𝜌5 − 𝑒𝑒6𝜌𝜌6 0 0 0 00 0 0 0 𝑒𝑒5𝜌𝜌5 −𝜌𝜌6 − 𝜌𝜌7 − 𝑑𝑑6 0 0 00 0 0 0 𝑒𝑒6𝜌𝜌6 𝜌𝜌6 −𝜌𝜌7 − 𝑑𝑑7 0 00 0 0 0 0 𝜌𝜌7 𝜌𝜌7 −𝜌𝜌8 − 𝑑𝑑8 00 0 0 0 0 0 0 𝜌𝜌8 −𝑑𝑑9⎠⎟
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𝐶𝐶𝑖𝑖,𝑗𝑗,1𝑛𝑛,𝑚𝑚
𝐶𝐶𝑖𝑖,𝑗𝑗,2𝑛𝑛,𝑚𝑚
𝐶𝐶𝑖𝑖,𝑗𝑗,3𝑛𝑛,𝑚𝑚
𝐶𝐶𝑖𝑖,𝑗𝑗,4𝑛𝑛,𝑚𝑚
𝐶𝐶𝑖𝑖,𝑗𝑗,5𝑛𝑛,𝑚𝑚
𝐶𝐶𝑖𝑖,𝑗𝑗,6𝑛𝑛,𝑚𝑚
𝐶𝐶𝑖𝑖,𝑗𝑗,7𝑛𝑛,𝑚𝑚
𝐶𝐶𝑖𝑖,𝑗𝑗,8𝑛𝑛,𝑚𝑚
𝐶𝐶𝑖𝑖,𝑗𝑗,9𝑛𝑛,𝑚𝑚⎠
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Infection terms 
The forces of infection below are concerned with acquiring infection.  The terms are of the form 
𝐹𝐹𝐹𝐹𝐼𝐼𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚 = 𝜆𝜆𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚𝑆𝑆𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚  
where 𝜆𝜆𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚  is the force of infection for the subcategory in question.  Relative risks of HCV 
transmission for recent injectors, non-recent injectors, high risk injectors, those on OST or NSP or 
both are 𝑋𝑋1,𝑋𝑋2,Ξ, Γ,Π and Β respectively. The spontaneous clearance rate of HCV is 𝛿𝛿 and the base 
transmission rate is 𝜋𝜋. When the ordinary differential equation is for susceptible the FOI term is 
subtracted and the same term is added to the matching infectious category. 
𝜆𝜆0,0,𝑘𝑘1,𝑙𝑙 = 𝜋𝜋Χ1(1 − 𝛿𝛿)Υ 
𝜆𝜆0,0,𝑘𝑘2,𝑙𝑙 = 𝜋𝜋𝑋𝑋2(1 − 𝛿𝛿)Υ 
𝜆𝜆0,0,𝑘𝑘3,𝑙𝑙 = 𝜋𝜋(1 − 𝛿𝛿)Υ 
𝜆𝜆0,0,𝑘𝑘1,ℎ = 𝜋𝜋Χ1Ξ(1 − 𝛿𝛿)Υ 
𝜆𝜆0,0,𝑘𝑘2,ℎ = 𝜋𝜋𝑋𝑋2Ξ(1 − 𝛿𝛿)Υ 
𝜆𝜆0,0,𝑘𝑘3,ℎ = 𝜋𝜋Ξ(1 − 𝛿𝛿)Υ 
𝜆𝜆0,1,𝑘𝑘𝑛𝑛,𝑚𝑚 = Γ𝜆𝜆0,0,𝑘𝑘𝑛𝑛,𝑚𝑚  
𝜆𝜆1,0,𝑘𝑘𝑛𝑛,𝑚𝑚 = Π𝜆𝜆0,0,𝑘𝑘𝑛𝑛,𝑚𝑚  
𝜆𝜆1,1,𝑘𝑘𝑛𝑛,𝑚𝑚 = Β𝜆𝜆0,0,𝑘𝑘𝑛𝑛,𝑚𝑚  
Define 
𝐶𝐶𝑛𝑛,𝑚𝑚 = ��𝐶𝐶0,0,𝑘𝑘𝑛𝑛,𝑚𝑚 𝐶𝐶0,1,𝑘𝑘𝑛𝑛,𝑚𝑚 𝐶𝐶1,0,𝑘𝑘𝑛𝑛,𝑚𝑚 𝐶𝐶1,1,𝑘𝑘𝑛𝑛,𝑚𝑚 �9
𝑘𝑘=1
, 
𝑆𝑆𝑛𝑛,𝑚𝑚 = ��𝑆𝑆0,0,𝑘𝑘𝑛𝑛,𝑚𝑚 𝑆𝑆0,1,𝑘𝑘𝑛𝑛,𝑚𝑚 𝑆𝑆1,0,𝑘𝑘𝑛𝑛,𝑚𝑚 𝑆𝑆1,1,𝑘𝑘𝑛𝑛,𝑚𝑚 �9
𝑘𝑘=1
, 
 𝐼𝐼 = �1Γ
Π
Β
�, 
to give 
Υ= (Χ1(𝐶𝐶1,𝑙𝑙 + Ξ𝐶𝐶1,ℎ) + 𝑋𝑋2�𝐶𝐶2,𝑙𝑙 + Ξ𝐶𝐶2,ℎ� + (𝐶𝐶3,𝑙𝑙 + Ξ𝐶𝐶3,ℎ))𝐼𝐼
�Χ1�𝐶𝐶1,𝑙𝑙 + 𝑆𝑆1,𝑙𝑙 + Ξ(𝐶𝐶1,ℎ + 𝑆𝑆1,ℎ)� + 𝑋𝑋2�𝐶𝐶2,𝑙𝑙 + 𝑆𝑆2,𝑙𝑙 + Ξ(𝐶𝐶2,ℎ + 𝑆𝑆2,ℎ)� + (𝐶𝐶3,𝑙𝑙 + 𝑆𝑆3,𝑙𝑙 + Ξ(𝐶𝐶3,ℎ + 𝑆𝑆3,ℎ))�𝐼𝐼  
 
Treatments 
There are a fixed number of treatments per year, given by Φ.  When the total number of infected 
individuals in the model is greater than this number, the treatments are allocated proportionately.  
When the total number of infected individuals is less than the number of possible treatments per 
year, all are treated.  Only the first two disease progression categories are eligible for treatment and 
will have treatment terms.  If the ordinary differential equation is for an infected category the 
treatment term will be subtracted and for a susceptible category the term will be added. 
If 
Φ < �� � 𝐶𝐶𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚
𝑚𝑚,𝑖𝑖,𝑗𝑗
3
𝑛𝑛
5
𝑘𝑘=1
= 𝐶𝐶𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡, 
𝑇𝑇𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚�𝐶𝐶𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚� = 𝛼𝛼Φ𝐶𝐶𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚𝐶𝐶𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 , 
for 𝑘𝑘 = 1,2 … 5,𝑛𝑛 = 1,2,3. 
Otherwise 
𝑇𝑇𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚�𝐶𝐶𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚� = 𝛼𝛼𝐶𝐶𝑖𝑖,𝑗𝑗,𝑘𝑘𝑛𝑛,𝑚𝑚, 
for 𝑘𝑘 = 1,2 … 5,𝑛𝑛 = 1,2,3. 
For ex-PWID treatment is more straightforward with a proportion, 𝑟𝑟 of the chronically infected and 
compensated cirrhosis individuals being treated each year.  
𝑇𝑇𝑘𝑘
4�𝐶𝐶𝑘𝑘
4� = 𝛼𝛼𝑟𝑟𝐶𝐶𝑘𝑘4, 
for 𝑘𝑘 = 1,2 … 5 
As an example here is the ordinary differential equation for the susceptible category for the first 
disease progression category, no interventions, recent injector (<3 years) and low risk.  On the right 
hand side in order from left to right there is an inflow term, injecting duration terms, intervention 
terms, high/low risk terms, disease progression terms, infection term and treatment term.   
𝑑𝑑𝑆𝑆0,0,11,𝑙𝑙
𝑑𝑑𝑑𝑑
= 𝜃𝜃(1 − 𝜙𝜙) + 𝐼𝐼𝐷𝐷0,0,11,𝑙𝑙 + 𝐼𝐼𝑇𝑇0,0,11,𝑙𝑙 + 𝐻𝐻𝑅𝑅0,0,11,𝑙𝑙 + 𝐷𝐷𝑆𝑆0,0,11,𝑙𝑙 − 𝜆𝜆0,0,11,𝑙𝑙 𝑆𝑆0,0,11,𝑙𝑙 + 𝑇𝑇0,0,11,𝑙𝑙  
 
MODEL PARAMETERS 
TABLE S2 MODEL PARAMETERS 
Parameter Symbol Value/Range Reference 
Epidemiological and Demographic parameters 
Number of new injectors 
per year 
𝜃𝜃 Fitted to obtain population 
sizes 
Bristol (21, 22), Walsall (22) and 
unpublished estimates, Dundee adjusted 
from (23).  See Table S2 and supporting 
information 
Combined death and 
cessation rates per year 
𝜇𝜇𝑖𝑖 Fitted to obtain injecting 
duration profiles for each 
setting 
Lower bounds of 0.004 and 0.008 were 
chosen to ensure the leaving rate was 
greater than the likely death rate (24). See 
Table S2 and supporting information 
Infection rate per year 𝜋𝜋 Fitted to obtain HCV 
prevalence required in each 
setting 
See Table S2 and supporting information 
Proportion of new 
infections which 
spontaneously clear 
𝛿𝛿 Sampled from uniform 
distribution (0.22-0.29) 
(15) 
Leaving rate per year from 
high to low risk behaviour 
𝜁𝜁 Sampled range (0.6761-1.617) Data from cohort study (12) found 78/145 
injectors no longer homeless after 8 
months. Transition probability sampled 
from beta distribution α= 78 and 𝛽𝛽 = 67 
and converted to instantaneous rate 
Recruitment rate per year 
from low risk to high risk 
behaviour 
𝜎𝜎 Fitted to obtain required high 
risk proportions in each setting 
See Table S2 and supporting information 
Intervention Related parameters 
Leaving rate per year off 
OST 
𝛾𝛾 1-3 Duration on OST was 8 months (4-12 
months) in cohort of PWID in UK (24) 
Leaving rate per year off 
HCNSP 
𝜅𝜅 0.37-0.77 Welsh cohort study 61% PWID still >100% 
NSP after 1 year.  Duration on NSP was 
1.3-2.7 years. (25) Recruitment rate per year on to OST 𝛽𝛽 Fitted to obtain required OST coverage proportions in each 
setting 
See Table S2 and supporting information 
Recruitment rate per year on to HCNSP 𝜂𝜂 Fitted to obtain required high NSP coverage proportions in 
each setting 
See Table S2 and supporting information 
Proportion of treatments 
achieving SVR  prior to 
2015 
𝛼𝛼 Sampled from uniform 
distribution (0.3992-0.6653)  
Weighted mean of pooled intention to 
treat SVR for genotypes 1 and 2/3 taken 
from treatment data for PWID in UK  (26) 
Proportion of treatments 
achieving SVR post 2015 
𝛼𝛼 Sampled from uniform 
distribution (0.859-0.915) 
(27)Weighted mean of SVR for genotype 1 
(90%) and genotypes 2/3 (82-93%) from 
(28). 
Number of PWID’s treated 
per year 
Φ Bristol – 18 
Dundee – 34 (2009 to 2015), 
and then 40 (2015 onwards) 
Walsall – 2 
Number of HCV treatments in 2011.  
Assumed treatment of PWIDs commenced 
in 2009(26).  More recent estimate for 
Dundee (personal communication John 
Dillon).  Walsall value assumed same rate 
per infected PWIDs as Bristol. 
Relative Transmission Risk parameters 
Risk associated with being 
on OST only 
Γ 0.41(0.22-0.75) sampled 
from Lognormal distribution 
Odds ratio and 95% CI from pooled 
analysis (in press NIHR report) 
Risk associated with being 
on HCNSP only 
Π 0.59(0.36-0.96) sampled 
from Lognormal distribution 
Odds ratio  and 95% CI from pooled 
analysis (in press NIHR report) 
Risk associated with being 
on both OST and HCNSP 
Γ × Π 0.26 (0.09-0.64)  Calculated as product of risk associated 
with being solely on OST or NSP. Compares 
well to estimate from systematic review 
0.29 (0.13-0.65) (in press NIHR report) 
Risk associated with being 
a recent injector 
compared to a long-term 
injector* 
Χ1 1.53(0.93-2.52) sampled 
from Lognormal distribution 
Odds ratio from pooled analysis (in press 
NIHR report) 
Risk associated with being 
in the high risk category 
Ξ Scotland: 2.13(1.40-3.24) 
Bristol and Walsall:  
2.75(1.97-4.22). Both 
sampled from lognormal 
distribution 
Odds ratio from pooled analysis. For 
Scotland, the OR is just for homelessness 
because there is little crack injection, 
whereas it is for crack injection or 
homelessness for Bristol and Walsall 
Parameter description symbol Distribution Source 
Yearly progression rate from 
f0 to f1 
𝜌𝜌1 0.529-0.2095 sampled from 
normal distribution 
PWID specific instantaneous rates from 
(29) 
 
 
Yearly progression rate from 
f1 to f2 
𝜌𝜌2 0.0216-0.1013 sampled from 
normal distribution 
Yearly progression rate from 
f2 to f3 
𝜌𝜌3 0.0450-0.1145 sampled from 
normal distribution 
 Yearly progression rate from 
f3 to compensated cirrhosis 
𝜌𝜌4 0.0513-0.1838 sampled from 
normal distribution 
Yearly progression rate from 
compensated cirrhosis to 
decompensated cirrhosis 
𝜌𝜌5 0.0166-0.0921 Instantaneous rates calculated from 
sampled beta distributions of transition 
probabilities in (16) 
Yearly progression rate from 
compensated cirrhosis or 
decompensated cirrhosis to 
hepatocellular carcinoma  
𝜌𝜌6 0.0003-0.0684 
Yearly progression rate from 
decompensated cirrhosis or 
HCC to liver transplant 
𝜌𝜌7 0.0062-0.0962 
Yearly progression rate from 
liver transplant to post liver 
transplant 
𝜌𝜌8 1.0423-2.4412 
Decompensated cirrhosis 
related death rate per year 
𝑑𝑑6 0.1063-0.1842 
Hepatocellular carcinoma 
related death rate per year 
𝑑𝑑7 0.3904-0.7697 
Liver transplant related 
death rate per year 
𝑑𝑑8 0.0911-0.4348 
Post liver transplant related 
death rate per year 
𝑑𝑑6 0.0280-0.1016 
Relative risk for progression 
rate from  compensated to 
decompensated cirrhosis 
(𝜌𝜌5) following SVR 
𝑒𝑒5 0.07 (95%CI 0.03,0.2) Sampled from transformed lognormal 
distribution (19) 
Relative risk for progression 
rate from compensated 
cirrhosis to HCC (𝜌𝜌6) 
following SVR 
𝑒𝑒6 0.23 (95%CI 0.16,0.35) Sampled from transformed lognormal 
distribution (18) 
MODEL CALIBRATION 
Model calibration was carried out in three steps with 1000 parameter sets obtained at each step: 
1. Population size and injecting duration fitting using a PWID demographic sub-model without 
infection. 
2. NSP and OST coverage fitting using a sub-model that includes HCV transmission but no disease 
progression. 
3. HCV prevalence fitting using the full model with disease progression. 
 
Step 1 
In Dundee, survey data (30) suggested that the proportion of the PWID population in each injecting 
duration category was stable from 2008 to 2014, and so we assumed a constant population size 
estimated from unpublished data from Scotland.  In Bristol and Walsall, size estimation data 
suggests that the PWID population has decreased by between 10% and 30% between 2009 and 2011 
(21, 22, 31, 32).  Concurrently, survey data(14, 30, 33-35) suggests the proportion of PWID injecting 
for longer than 10 years has increased whilst the proportion injecting for between 3 and 10 years 
decreased as shown in Figure 4.2a and 4.2b. There has been little change in the proportion injecting 
for less than 3 years. It was assumed that these changes were partly due to a decrease in the 
initiation rate of new injectors and a change in the cessation rates of non-recent and long-term 
injectors. We allowed for uncertainty around these parameters and estimated them by fitting the 
model to the population size and injecting duration profile (proportion of PWID in each injecting 
duration category) at two points in time for Walsall and Bristol and one time point for Dundee. This 
fitting was done with a demographic sub-model, which only had three injecting duration categories 
and no other stratification. We assumed that the PWID population size was at equilibrium initially 
(before 2004, 2006 and 2008 for Bristol, Walsall and Dundee, respectively). We sampled 1000 values 
for this ‘stable’ initial population size and the cessation rate from the recent injector category for 
each setting. For each of these 1000 parameter sets, the wide prior distributions for the cessation 
rates from non-recent and long-term injectors (see Supplementary Table 2) were then sampled, and 
for each sample the model was fit to the initial population size by calculating a suitable PWID 
recruitment rate using the steady state equations for the demographic sub-model (more details in 
Appendix 1).  Parameter sets were retained if the resulting injecting duration profile lay within the 
ranges suggested from data, otherwise the cessation rates were resampled.  We then sampled 1000 
estimates for the later population size in 2011 for Bristol and Walsall, as well as new cessation rates 
for non-recent and long-term injectors, and the PWID recruitment rate was re-calibrated to fit to this 
new sampled population size for the 2011 data (only Bristol and Walsall). This refitting of the 
demographic sub-model was done using the Matlab algorithm fzero applied to the analytic solution 
of the model with initial conditions from the first step of fitting.  Parameter sets were retained if the 
resulting injecting duration profile lay within ranges suggested from data for years 2004 and 2011 
for Bristol and 2008 and 2011 for Walsall, otherwise the new cessation rates for this second step 
were resampled to obtain a fit to each of the first step parameter sets (1000 each for Bristol and 
Walsall).    
 
Step 2 
Coverage levels for PWID currently on OST have increased over the last 12 years.  In Bristol, the 
proportion of PWID currently on OST increased from 40% in 2004 (33) up to 81% in 2009(14).  In 
Walsall, OST coverage increased from 40% in 2006 to 70% in 2009 (36), and in Dundee it increased 
from 43% in 2008 to 72% in 2014 (37). Conversely, over this same time period, the proportion of 
PWID with >100% NSP coverage remained stable in both Bristol (55%) (14, 30, 33) and Walsall (38%) 
(30), while it increased over time in Dundee from 41% in 2008 to 60% in 2014(30).  Modelled OST 
coverage levels for each city were calibrated to this coverage data by varying the recruitment rate 
onto each intervention.  A service provision estimate of NSP coverage was calculated for each setting 
using data on needles distributed from the costings analysis (2014 data), population size (calculated 
from the model in 2014) and injecting frequency from survey data.  Bootstrap samples of the mean 
injecting frequency were calculated for each setting using UAM (Bristol and Walsall) and NESI 
(Dundee) data.  In addition the mean injecting frequency in Dundee has decreased from 717 
injections per year in 2008 to 388 injections per year in 2014.  Therefore an estimate of NSP 
coverage was calculated for each time point. The average service provision estimates of NSP 
coverage were 56% and 28% in Bristol and Walsall respectively in 2014 and 27% and 49% in 2008 
and 2014 respectively for Dundee (see Supplementary Table 2 for more details).  The recruitment 
rates were estimated using an intervention sub-model that incorporated no onward disease 
progression as these mechanisms have little effect on the coverage levels obtained.  Using the 
Matlab fitting algorithm lsqnonlin, recruitment rates were found to fit the sub-model to the initial 
and endpoint coverage of each intervention as shown in Supplementary Table 2, while assuming 
coverage levels were quasi stable. In the full model, the recruitment rates for the initial coverage 
level was first used to obtain initial conditions for the first time point for each city, and then the 
recruitment rate was gradually varied linearly between the two values to obtain the required 
increase in coverage for that city. 
 
Survey data suggests that the prevalence of crack injecting and/or homelessness, our markers of 
high HCV transmission risk, have remained stable in Dundee (33% homeless) and Walsall (52% 
homeless or crack injection), whereas it has increased in Bristol from 75% in 2004 to 87% in 2014 
(homeless or crack injection).  We assumed that a proportion of injectors are high-risk when they 
initiate injecting, which is consistent with available data(12).  The leaving rate from these high-risk 
categories was estimated from a cohort study on homelessness which found that approximately two 
thirds of homeless PWID are no longer homeless after one year(12).  This agrees with unpublished 
findings from a Welsh cohort study for both crack and homelessness(11, 25). The leaving rate was 
sampled 1000 times and used for all three setting.  The proportion of PWID that are high-risk was 
also sampled 1000 times for each setting.  The recruitment rates were then calculated for each 
parameter set using the steady state solution of the high/low risk sub-model (two variables). In 
Bristol, where the proportion of PWID that are high-risk has increased, we calculated a second 
recruitment rate for the second time point (2014) using the same method.  For Bristol, the 
recruitment rate was gradually varied linearly to obtain the increase in the proportion of PWID that 
are high-risk.   
 
Step 3 
The last step of the model calibration involved fitting the full model to the HCV prevalence data from 
each setting (sampled 1000 times from the ranges given in Supplementary Table 2).  This 
incorporated the 1000 parameter sets from the previous model calibration steps, and involved 
calibrating the model’s infection rate using the lsqnonlin function in Matlab.  The model was first fit 
to the initial prevalence estimate (sampled from the ranges given in Supplementary Table 2) in 2004, 
2006 and 2008 for Bristol, Walsall and Dundee, respectively (Supplementary Figure 1 and 
Supplementary Table 2), while assuming the epidemic was in a stable state at that time. For Walsall 
and Bristol, this one infection rate well captured the subsequent baseline epidemic dynamics 
(slightly increasing in Bristol and Walsall) and so no change in the infection rate was assumed after 
that point.  The baseline transmission rates in Bristol and Walsall were comparable (0.07-0.21 and 
0.09-0.22 respectively), whereas Dundee had a slightly higher baseline transmission risk (0.16-0.39. 
However, for Dundee we needed to fit a second increased infection rate (0.36-0.94) to capture the 
increase in HCV prevalence from 2008 to 2014 (using the parameters from the first prevalence fitting 
step as the initial conditions). This either suggests the epidemic was not stable in 2008 or that there 
has been a change in the risk profile of PWID in Dundee that is not fully captured by changes in 
intervention coverage or the prevalence of high-risk behaviours. Supplementary Table 2 and 
Supplementary Figure 1 show the model parameters that were fitted in the model.   
 
TABLE S3 SUMMARY OF DATA COLLATED FOR EACH SETTING FOR MODEL CALIBRATION 
 Bristol  Walsall Dundee Relevant parameter 
Current 
PWID 
population 
size 
2004:  
sampled 111-125% 
(22) of 2011 
value(21). 
2011:  
2025-2564 adjusted 
from(21)  to include 
only 60% of people 
on OST not in 
contact with other 
services (21).  
Sampled    
uniformly 
2006: 
125%(22) of 2011 
value 
2011: 
1296-1623 
estimated from 
local number on 
OST and 
unpublished PWID 
prevalence 
estimates for West 
Midlands. Sampled    
uniformly 
Constant level  
675-825 local 
estimate adjusted 
from (23) 
Sampled    
uniformly 
𝜃𝜃, Number of new injectors per 
year 
 
Value of 𝜃𝜃 found using steady 
state equations of population sub-
model for the first time point in all 
3 settings.  In Bristol and Walsall a 
second value of 𝜃𝜃 is found using 
Matlab fzero and analytical 
solution  to population sub-model 
that gives population size required 
with sampled cessation rates 
Injecting 
duration 
profile: 
Proportion of 
PWID that 
are recent 
(R),  non-
recent (NR),  
or long-term 
injectors (LT) 
2004:  
R: 0.04-0.2 
NR: 0.25-0.45 
LT: 0.4-0.65 (UAM) 
2014:  
R: 0.075-0.2 
NR: 0.05-0.22 
LT: 0.55-0.85 (UAM) 
 
2006:  
R: 0.1-0.3 
NR: 0.45-0.65 
LT: 0.2-0.3  
2014:  
R:0.1-0.3 
NR: 0.15-0.4 
LT: 0.4-0.6 
(UAM) 
Constant level  
R: 0.15-0.35 
NR: 0.36-0.65 
LT: 0.12-0.35 
(NESI) 
Death and cessation rates (𝜇𝜇𝑖𝑖) per 
year.  Prior distribution for 𝜇𝜇1 
(0.0351 – 0.1702) calculated from 
assumption that between 10% and 
40% of recent initiates cease 
injecting within 3 years (7).  A 
large upper bound of 0.4 was 
assumed for the prior distributions 
of 𝜇𝜇2 and 𝜇𝜇3 due to lack of 
information.  Lower bounds of 
0.004 and 0.008 were chosen to 
ensure the leaving rate was 
greater than the likely death rate 
(24) 
 
Parameter sets accepted if PWID 
demographic sub-model fits were 
within the ranges for each 
injecting duration 
Chronic HCV 
Prevalence 
(75% of HCV 
Ab 
prevalence) 
Constant level 40-
50% (community 
surveys, UAM) 
Sampled from 
truncated 
Beta(305.25,364.75) 
2006:  
11-26% (UAM) 
Sampled from 
truncated 
Beta(30.75,132.25) 
2014:   
2008:  
15-30% (NESI) 
Sampled from 
truncated 
Beta(18.75,64.25) 
2014:  
𝜋𝜋, infection rate used to fit the 
HCV prevalence estimates 
15-39% (no fitting 
required) 
19-32% adjusted 
from (NESI) 
Sampled from 
truncated 
Beta(43.45,125.55)* 
Proportion 
high risk 
2004:  
70-80% (2004, 2006 
community surveys 
and UAM). Sampled 
uniformly. 
2014:  
80-95% (UAM). 
Sampled uniformly.  
Constant level of 
40-65% (UAM). 
Sampled 
uniformly. 
Constant level of 
26-42% (NESI). 
Sampled from Beta 
(156,315). 
 
𝜙𝜙, proportion of injectors initially 
high risk assumed same as 
sampled proportion high risk 
𝜎𝜎, recruitment rate per year from 
low to high risk behaviour, 
calculated from sampled leaving 
rate 𝜁𝜁 and proportion high risk 𝜙𝜙. 
Proportion 
on OST 
2004:   
33.3-46.7% (38) 
sampled from 
truncated 
Beta(81,121) 
2009:  
76.5-86.3% 
(community survey, 
2009) sampled from 
truncated 
Beta(241,55) 
2006:  
30-50% (UAM) 
sampled from 
truncated 
Beta(32,48) 
2009:  
61-82% (UAM)  
sampled from 
truncated 
Beta(47,18) 
2008:   
433-53% (NESI) 
sampled from 
Beta(36,47) 
2014:  
65-79% (NESI) 
sampled from 
Beta(106,40) 
𝛽𝛽, recruitment rate per year onto 
OST 
Proportion 
>100% NSP 
(needles 
distributed 
/(population  
size*injecting 
frequency)) 
Needles distributed 
in 2014 (786542-
844646), population 
size in 2014 and 
injecting frequency 
(470-859 per year 
from UAM) 
sampled. Mean 
calculated coverage 
56% 
 
Needles 
distributed in 2014 
(225275-237111), 
population size in 
2014 and injecting 
frequency (435-
716 per year from 
UAM) sampled. 
Mean calculated 
coverage 28% 
Needles distributed 
in 2014 (assumed 
same in 2008), 
population size in 
2008 and injecting 
frequency (517-999 
per year from NESI) 
sampled. 
Mean calculated 
coverage 27%. 
Needles distributed 
in 2014 (138246-
145768), population 
size in 2014 and 
injecting frequency 
(251-533 per year 
from NESI) 
sampled. 
Mean calculated 
coverage 49% 
𝜂𝜂, recruitment rate per year onto 
high coverage NSP 
• *Chronic prevalence  was available from the  NESI survey for 2014
SUB-MODELS USED IN THE FITTING PROCEDURE 
Injecting duration model 
A model with 3 injecting duration categories was used to fit the population data and the injecting 
duration profiles from survey data.  Here 𝑆𝑆𝑖𝑖 is the number of susceptible injectors in the 𝑖𝑖 category. 
The categories are: 𝑟𝑟, recent injector, 𝑛𝑛, non-recent injector and 𝑙𝑙, long-term injector.  The 𝜇𝜇𝑖𝑖  and 𝜏𝜏𝑖𝑖 
are the same as the full model. 
𝑑𝑑𝑆𝑆𝑡𝑡
𝑑𝑑𝑑𝑑
= 𝜃𝜃 − (𝜇𝜇1 + 𝜏𝜏1)𝑆𝑆𝑡𝑡 
𝑑𝑑𝑆𝑆𝑛𝑛
𝑑𝑑𝑑𝑑
= 𝜇𝜇1𝑆𝑆𝑡𝑡 − (𝜇𝜇2 + 𝜏𝜏2)𝑆𝑆𝑛𝑛 
𝑑𝑑𝑆𝑆𝑙𝑙
𝑑𝑑𝑑𝑑
= 𝜇𝜇2𝑆𝑆𝑛𝑛 − 𝜇𝜇3𝑆𝑆𝑙𝑙 
 
The steady state solution of this model is given below: 
 
𝑆𝑆𝑡𝑡 = 𝜃𝜃
𝜇𝜇1+𝜏𝜏1
, 𝑆𝑆𝑛𝑛 = 𝜃𝜃𝜏𝜏1(𝜇𝜇1+𝜏𝜏1)(𝜇𝜇2+𝜏𝜏2) , 𝑆𝑆𝑙𝑙 = 𝜃𝜃𝜏𝜏1𝜏𝜏2�𝜇𝜇3(𝜇𝜇1+𝜏𝜏1)(𝜇𝜇2+𝜏𝜏2)�, 
 
with total population  𝑁𝑁 = 𝑆𝑆𝑡𝑡 + 𝑆𝑆𝑛𝑛 + 𝑆𝑆𝑙𝑙 .
The analytical solution of this system is 
 
𝑆𝑆𝑡𝑡(𝑑𝑑) = 𝑆𝑆𝑡𝑡(0)𝑒𝑒−(𝜇𝜇1+𝜏𝜏1)𝑡𝑡 + 𝜃𝜃
𝜇𝜇1+𝜏𝜏1
�1 − 𝑒𝑒−(𝜇𝜇1+𝜏𝜏1)𝑡𝑡�, 
𝑆𝑆𝑛𝑛(𝑑𝑑) = 𝜏𝜏1𝜃𝜃(𝜇𝜇1 + 𝜏𝜏1)(𝜇𝜇2 + 𝜏𝜏2) + 𝑆𝑆𝑛𝑛(0)𝑒𝑒−(𝜇𝜇2+𝜏𝜏2)𝑡𝑡 + 𝜏𝜏1𝜇𝜇1 + 𝜏𝜏1 − 𝜇𝜇2 − 𝜏𝜏2 𝑆𝑆𝑡𝑡(0)(𝑒𝑒−(𝜇𝜇2+𝜏𝜏2)𝑡𝑡 − 𝑒𝑒−(𝜇𝜇1+𝜏𝜏1)𝑡𝑡)+ 𝜏𝜏1𝜃𝜃
𝜇𝜇1 + 𝜏𝜏1 − 𝜇𝜇2 − 𝜏𝜏2 ∗  (𝑒𝑒−(𝜇𝜇1+𝜏𝜏1)𝑡𝑡/ (𝜇𝜇1 + 𝜏𝜏1) − 𝑒𝑒−(𝜇𝜇2+𝜏𝜏2)𝑡𝑡/(𝜇𝜇2 + 𝜏𝜏2)),    
 
𝑆𝑆𝑙𝑙(𝑑𝑑) = 𝑒𝑒−𝜇𝜇3𝑡𝑡 �𝑆𝑆𝑙𝑙(0) + 𝜏𝜏2
𝜇𝜇2 + 𝜏𝜏2 − 𝜇𝜇3 .� 𝜏𝜏1𝑆𝑆𝑡𝑡(0)𝜇𝜇1 + 𝜏𝜏1 − 𝜇𝜇3 − 𝜏𝜏1𝜃𝜃𝜇𝜇3(𝜇𝜇1 + 𝜏𝜏1 − 𝜇𝜇3) + 𝑆𝑆𝑛𝑛(0)��+ 𝑒𝑒−(𝜇𝜇2+𝜏𝜏2)𝑡𝑡𝜏𝜏2
𝜇𝜇2 + 𝜏𝜏2 − 𝜇𝜇3 � 𝜏𝜏1𝑆𝑆𝑡𝑡(0)𝜇𝜇2 − 𝜏𝜏2 + 𝜇𝜇1 + 𝜏𝜏1 + 𝜏𝜏1𝜃𝜃(𝜇𝜇2 + 𝜏𝜏2)(−𝜇𝜇2 − 𝜏𝜏2 + 𝜇𝜇1 + 𝜏𝜏1) − 𝑆𝑆𝑛𝑛(0)�+ 𝑒𝑒−(𝜇𝜇1+𝜏𝜏1)𝑡𝑡𝜏𝜏1𝜏𝜏2𝜃𝜃(𝜇𝜇1 + 𝜏𝜏1)(𝜇𝜇1 + 𝜏𝜏1 − 𝑚𝑚𝑢𝑢3)(𝜇𝜇1 + 𝜏𝜏1 − 𝜇𝜇2 − 𝜏𝜏2) + 𝜏𝜏1𝜏𝜏2𝜃𝜃𝜇𝜇3(𝜇𝜇1 + 𝜏𝜏1)(𝜇𝜇2 + 𝜏𝜏2) 
 
High risk model 
A model with a high risk and low risk only was used to calculate parameter values in the 
calibration process. The variable 𝑆𝑆ℎ denotes high risk and 𝑆𝑆𝑙𝑙  denotes low risk. 
 
𝑑𝑑𝑆𝑆ℎ
𝑑𝑑𝑑𝑑
= −𝜁𝜁𝑆𝑆ℎ + 𝜎𝜎𝑆𝑆𝑙𝑙  
𝑑𝑑𝑆𝑆𝑙𝑙
𝑑𝑑𝑑𝑑
= 𝜁𝜁𝑆𝑆ℎ − 𝜎𝜎𝑆𝑆𝑙𝑙 
 
As this is a closed system we have: 𝑁𝑁 − 𝑆𝑆ℎ = 𝑆𝑆𝑙𝑙, which gives 
𝑑𝑑𝑆𝑆ℎ
𝑑𝑑𝑑𝑑
= −𝜁𝜁𝑆𝑆ℎ + 𝜎𝜎(𝑁𝑁 − 𝑆𝑆ℎ) 
Setting the left hand side to zero and solving gives to obtain the proportion of the total population 
that are high risk 
Φ = 𝜎𝜎
𝜎𝜎 + 𝜁𝜁 
This expression was used to calculate the required value of the recruitment rate 𝜎𝜎, from the sampled 
values of the proportion of high risk individuals and the leaving rate 𝜁𝜁. 
 
 
 
 
 
 
 
FIGURE S1 GRAPHS SHOWING FITTING OF THE BASELINE SCENARIOS IN EACH SETTING.   
Error bars in black are data points from surveys, error bars in red are the ranges used for model calibration. 
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MODEL PARAMETRIZATION AND CALIBRATION 
In order to capture costing uncertainty within the cost-effectiveness model, we conducted a 
multivariate simulation of all parameters included in the costing sensitivity analysis (described 
above), with uniform distribution between the minimum and the maximum values observed over 
1000 iterations.  The results from these 1000 iterations were fed in as the cost estimates for NSPs in 
the cost-effectiveness model. 
Other health-related costs and QALY weights as derived from the literature were input into the 
model using appropriate distributions, as described in Table S1.  Cost parameters were largely varied 
with a Gamma distribution, with the exception of treatment costs for sofosbuvir and ledipasvir; 
these were kept as a constant because of lack of data for a distribution.  QALY weights were varied 
using a Beta distribution. 
 
RESULTS 
TABLE S2 DETAILED COSTING RESULTS 
  
Total 
Needles Total Cost 
Non-IPED 
PWID 
population 
size 
Visits 
per 
user 
Cost per non-
IPED PWID 
Needles 
per non-
IPED PWID 
Bristol 883,524 £232,116.78 1,847-2,595 13-18 £89.45-£125.67 340-478 
Dundee 150,790 £104,495.75 675-825 17-20 £126.66-£154.81 183-223 
Walsall 245,002 £98,649.03 1,144-1,646 12-17 £59.93-£86.23 149-214 
 
 
TABLE S3 TOTAL COSTS AND NEEDLES FOR DISTRIBUTION TO OPIATE USERS, BY CITY  
Total Needles           
Bristol 
    
Fixed Site       
Pharmacies (n = 25)       
Other       
Total City-Wide       
Dundee     
Fixed Site       
Pharmacies (n = 5)       
Other                 
Total City-Wide       
Walsall     
Fixed Site       
Pharmacies (n = 12)       
Other       
Total City-Wide       
 
FIGURE S2 COSTING SENSITIVITY ANALYSIS 
 
 
TABLE S4 TOTAL DEATHS AND INFECTIONS AVERTED THOUGH NSP OVER 50 YEARS BY CITY 
 Deaths Averted Infections Averted 
 Median 2.5% CrI 97.5% CrI Median 2.5% CrI 97.5% CrI 
Bristol 20.5 4.3 51.1 199.5 42.5 505.2 
Dundee 2.1 0.2 24.4 84 12 663 
Walsall 5.8 1.2 14.9 92.7 22.3 200.5 
CrI – credible interval 
Table S7 Projected total health-related costs over 50 years (GBP millions), by city 
 
Projected total health-related costs over 50-year 
time horizon (GBP millions) 
 
 With NSP No NSP for 10 years  
 Costs (2014 GBP) Mean 
2.5% 
CrI 
97.5% 
CrI Mean 
2.5% 
CrI 
97.5% 
CrI 
Mean 
Difference 
Bristol 
      
 
Healthcarea £130.4 £60.0 £288.4 £131.6 £60.8 £290.1 -£1.20 
HCV treatmentb (no injecting)  £39.9 £23.9 £58.2 £41.1 £24.8 £60.1 -£1.20 
HCV treatment (PWID) £15.5 £13.6 £16.1 £15.5 £14.1 £16.1 -£0.05 
NSP £6.0 £3.7 £8.3 £3.8 £2.3 £5.3 £2.20 
0-100% -50% 50% 100%
0-100% -50% 50% 100% 0-100% -50% 50% 100%
Bristol City
 Walsall City 
 Dundee City 
Bristol City
 Walsall City 
 Dundee City 
Bristol City
 Walsall City 
 Dundee City 
Bristol City
 Walsall City 
 Dundee City 
Bristol City
 Walsall City 
 Dundee City 
Bristol City
 Walsall City 
 Dundee City 
Bristol City
 Walsall City 
 Dundee City 
Bristol City
 Walsall City 
 Dundee City 
All  Parameters Discount Rate Equipment Wastage
Needle packs per transaction Opportunity cost of volunteer time Percent of needles to non-IPED users
Salaries multiplier Visits per Client
Total Non-IPED Costs (% difference from basecase)
Costing Sensitivity Analysis
OST £112.3 £86.8 £142.5 £112.2 £86.8 £142.4 £0.08 
Total £304.0   £304.1   -£0.16 
           
Dundee          
Healthcarea £32.2 £16.4 £68.0 £32.6 £16.7 £69.2 -£0.40 
HCV treatmentb (no injecting)  £11.4 £7.2 £16.4 £12.0 £7.5 £17.9 -£0.60 
HCV treatment (PWID) £8.8 £5.2 £14.1 £11.4 £5.6 £21.7 -£2.50 
NSP  £2.9 £1.6 £4.4 £1.9 £1.0 £2.8 £1.00 
OST  £37.1 £32.1 £42.3 £37.1 £32.1 £42.3 £0.0003 
Total  £92.5   £95.0   -£2.50 
           
Walsall          
Healthcarea  £64.1 £31.2 £132.4 £64.5 £31.4 £132.9 -£0.40 
HCV treatmentb (no injecting) £23.3 £15.1 £33.1 £23.9 £15.6 £34.0 -£0.60 
HCV treatment (PWID) £1.7 £1.6 £1.8 £1.7 £1.7 £1.8 -£0.002 
NSP  £3.0 £1.6 £5.3 £1.9 £1.0 £3.5 £1.10 
OST  £61.7 £38.3 £96.5 £61.7 £38.3 £96.5 £0.01 
Total  £153.8     £153.7      £0.10  
CrI – credible interval, ahealthcare costs include costs associated with disease stage (for example 
liver transplantation and management of hepatocellular carcinoma), bHCV treatment costs include 
drug and staff time associated with treating HCV; NSP, Needle and syringe programmes; HCV, 
hepatitis C virus; OST, opioid substitution therapy; PWID, people who inject drugs. 
 
Figure S3 Cost-effectiveness planes for each setting 
Bristol  
 Dundee 
 
Walsall 
 WTP, willingness to pay threshold; QALY, quality adjusted life year. 
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